Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis

被引：0
|
作者：
Simpson, Eric [1 ]
Boguniewicz, Mark [2 ,3 ]
Eichenfield, Lawrence [4 ]
Gonzales, Mercedes E. [5 ]
Hebert, Adelaide A. [6 ]
Prajapati, Vimal H. [7 ,8 ]
Gooderham, Melinda [9 ,10 ]
Krupa, David [11 ]
Chu, David H. [11 ]
Higham, Robert C. [11 ]
Berk, David R. [11 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR USA
[2] Natl Jewish Hlth, Denver, CO USA
[3] Univ Colorado, Sch Med, Aurora, CO USA
[4] Univ Calif San Diego, Radys Childrens Hosp San Diego, San Diego, CA USA
[5] Pediat Skin Res LLC, Miami, FL USA
[6] UT Hlth, McGovern Med Sch, Houston, TX USA
[7] Skin Hlth Wellness Ctr, Dermatol Res Inst & Prob Med Res, Calgary, AB, Canada
[8] Univ Calgary, Calgary, AB, Canada
[9] SKiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada
[10] Queens Univ, Peterborough, ON, Canada
[11] Arcutis Biotherapeut Inc, Westlake Village, CA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
atopic dermatitis; efficacy; patient-reported outcomes; roflumilast cream; safety;
D O I：
10.1093/bjd/ljae266.022
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
641
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Alonso-Llamazares, Javier
    Draelos, Zoe D.
    Ferris, Laura K.
    Forman, Seth B.
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Kircik, Leon H.
    Lomaga, Mark
    Moore, Angela
    Papp, Kim A.
    Prajapati, Vimal H.
    Hanna, Diane
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Almaraz, Erin
    Higham, Robert C.
    Chu, David H.
    Berk, David R.
    JAMA DERMATOLOGY, 2024,
  • [2] Efficacy and safety of roflumilast cream 0.15% in adults and children aged=6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
    Simpson, Eric
    Eichenfield, Lawrence
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide
    Papp, Kim
    Prajapati, Vimal
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [3] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Simpson, Eric L.
    Blauvelt, Andrew
    Gooderham, Melinda
    Lain, Edward
    Chu, David H.
    Higham, Robert C.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
  • [4] ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED RESULTS: FROM INTEGUMENT-1/2 PHASE 3 TRIALS
    Eichenfield, L.
    Boguniewicz, M.
    Simpson, E.
    Blauvelt, A.
    Gooderham, M.
    Lain, E.
    Chu, D.
    Higham, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S91 - S91
  • [5] EFFICACY AND SAFETY OF ROFLUMILAST CREAM 0.15% IN ADULTS AND CHILDREN AGED 6 AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS IN TWO PHASE 3 INTEGUMENT TRIALS
    Simpson, E.
    Eichenfield, L. F.
    Gooderham, M.
    Gonzalez, M.
    Hebert, A. A.
    Papp, K. A.
    Prajapati, V
    Krupa, D.
    Burnett, P.
    Berk, D. R.
    Higham, R.
    VALUE IN HEALTH, 2023, 26 (06) : S40 - S40
  • [6] Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies
    Simpson, Eric L.
    Augustin, Matthias
    Thaci, Diamant
    Misery, Laurent
    Silverberg, Jonathan I.
    Armstrong, April W.
    Fuxench, Zelma C. Chiesa
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB178 - AB178
  • [7] Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis
    Paller, Amy S.
    Gold, Linda Stein
    Soung, Jennifer
    Tallman, Anna M.
    Rubenstein, David S.
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (03) : 632 - 638
  • [8] Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial
    Eichenfield, Lawrence
    Browning, John
    Funk, Tracy
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Lee, Mark
    Prajapati, Vimal H.
    Serrao, Rocco
    Swanson, Lisa
    Higham, Robert
    Berk, David
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [9] Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: Pooled Results from two phase 3 studies
    Eichenfield, Lawrence F.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB158 - AB158
  • [10] Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials
    Igarashi, Atsuyuki
    Tsuji, Gaku
    Fukasawa, Shuichi
    Murata, Ryusei
    Yamane, Satoshi
    JOURNAL OF DERMATOLOGY, 2024,
12345